Drug Profile
ESP 01
Alternative Names: Breast cancer therapeutic - Espera Pharma; ESP-01Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Esperas Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours